Stockwatch: Curve Balls Divert The Santa Rally
This article was originally published in Scrip
A few minutes into the first of trading day of December with the stock market in positive territory the phrase Santa rally was echoing like a Christmas carol through trading rooms and investment desks. There is still no reason to believe that December will end on a negative note for life science stocks but there were enough curve balls thrown last week to result in more than one stumble amongst Santa's usually surefooted helpers.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.